We are live on ! Find out more
AGRX

Agile Therapeutics
AGRX

Delisted

AGRX was delisted on the 25th of March, 2024.

Back to rankings

46 hedge funds and large institutions have $63.4M invested in Agile Therapeutics in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,900% more call options, than puts

Call options by funds: $40K | Put options by funds: $1K

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

2% more funds holding

Funds holding: 45 → 46 (+1)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

0% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 13

3% less capital invested

Capital invested by funds: $65.5M → $63.4M (-$2.06M)

Holders
46
Holders Change
+1
Holders Change %
+2.22%
% of All Funds
1.05%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
6
Increased
13
Reduced
13
Closed
5
Calls
$40K
Puts
$1K
Net Calls
+$39K
Net Calls Change
-$233K

Top Buyers

Rank Fund Capital Flow
1
JGC
J. Goldman & Co
New York
+$1.93M
2
Franklin Resources
Franklin Resources
California
+$1.61M
3
PA
Perceptive Advisors
New York
+$496K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$304K
5
Renaissance Technologies
Renaissance Technologies
New York
+$278K

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$964K
2
RA
Royce & Associates
New York
-$793K
3
OAM
Oxford Asset Management
United Kingdom
-$483K
4
Russell Investments Group
Russell Investments Group
United Kingdom
-$469K
5
Barclays
Barclays
United Kingdom
-$205K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jacobs Levy Equity Management
26
Jacobs Levy Equity Management
New Jersey
$80K – – –
VF
27
Virtu Financial
New York
$76K -$185K -28 -65%
FPC
28
Falcon Point Capital
California
$71K -$119K -18 -56%
Barclays
29
Barclays
United Kingdom
$64K -$205K -31 -72%
OAM
30
Oxford Asset Management
United Kingdom
$61K -$483K -73 -86%
PAM
31
Panagora Asset Management
Massachusetts
$50K +$13.2K +2 +25%
Goldman Sachs
32
Goldman Sachs
New York
$34K -$6.61K -1 -13%
PPA
33
Parametric Portfolio Associates
Washington
$27K -$6.61K -1 -17%
Acadian Asset Management
34
Acadian Asset Management
Massachusetts
$24K +$33.1K +5 New
UBS Group
35
UBS Group
Switzerland
$10K +$13.2K +2 New
IA
36
IFP Advisors
Florida
$9K – – –
TRCT
37
Tower Research Capital (TRC)
New York
$8K +$13.2K +2 New
CIBC Private Wealth Group
38
CIBC Private Wealth Group
Georgia
$6K – – –
QCG
39
Quadrant Capital Group
Ohio
$6K – – –
Group One Trading
40
Group One Trading
Illinois
$5K – – –
Manulife (Manufacturers Life Insurance)
41
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4K – – –
Wells Fargo
42
Wells Fargo
California
$4K – – –
Deutsche Bank
43
Deutsche Bank
Germany
$3K -$72.7K -11 -92%
Bank of Montreal
44
Bank of Montreal
Ontario, Canada
$3K – – –
MAM
45
Meeder Asset Management
Ohio
$3K – – –
SIS
46
Sound Income Strategies
Florida
$3K +$6.61K +1 New
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$1.34K – – –
BC
48
Broadfin Capital
New York
– -$964K -179 Closed
Millennium Management
49
Millennium Management
New York
– -$112K -21 Closed
Janney Montgomery Scott
50
Janney Montgomery Scott
Pennsylvania
– -$108K -20 Closed
1
2
3

AGRX Hedge Fund Activity: Q1 2018 in Review

46 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q1 2018, worth a combined $63.4M — down 3.1% from $65.5M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new AGRX positions and 5 closed out — a net gain of 1 holder — while 13 added to existing stakes and 13 trimmed.

The largest buyer was J. Goldman & Co, opening a new position worth an estimated $1.93M. The largest seller was Broadfin Capital, exiting entirely with an estimated $964K sold.

  • 46 institutional investors held Agile Therapeutics (AGRX) as of Q1 2018, up from 45 in Q4 2017.
  • Funds reported $63.4M of Agile Therapeutics stock for Q1 2018, down 3.1% quarter-over-quarter.
  • 6 funds opened new Agile Therapeutics positions in Q1 2018 and 5 closed out, a net change of +1 holder.
  • The largest Agile Therapeutics buyer in Q1 2018 was J. Goldman & Co, an estimated $1.93M added.
  • The largest Agile Therapeutics seller in Q1 2018 was Broadfin Capital, an estimated $964K sold.

Based on aggregated 13F filings for Q1 2018.